Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTRUSION PK/PD study of tusamitamab ravtansine
NL-OMON53749Phase 2Withdrawn
- Sponsor
- Erasmus MC
- Start
- Mar 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tusamitamab ravtansine in Non-small cell lung cancer (NS-NSCLC), breast cancer and gastric cancer (GC), sponsored by Erasmus MC. Primary endpoint: Correlation between intratumoral DM4 concentration and maximal tumor size deviation. Planned start Mar 2023; status: withdrawn.
02
Drugs
tusamitamab ravtansine
03
Conditions
Non-small cell lung cancer (NS-NSCLC)breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON53749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53749.